HIV/AIDS Topics ASM Microbe 2016: Atripla 3 Times Weekly Maintains HIV Viral Suppression
- Details
- Category: HIV Treatment
- Published on Wednesday, 29 June 2016 00:00
- Written by Liz Highleyman
People with undetectable viral load who switched from taking the Atripla single-tablet regimen (efavirenz/tenofovir/emtricitabine) every day to just every other weekday were able to maintain viral suppression for 6 months, and longer follow-up is planned, according to research presented last week at the ASM Microbe conference in Boston.
New California Grants Address Disparities in HIV Prevention and Care
- Details
- Category: HIV Treatment
- Published on Wednesday, 29 June 2016 00:00
- Written by California HIV/AIDS Research Program
An $9 million effort funded by the California HIV/AIDS Research Program (CHRP) will create new interventions tailored to reach heard-to-reach and heavily impacted groups living with or at risk for HIV, including homeless youth, HIV-positive young men of color, young people who use drugs or alcohol, the House Ball community, and women with barriers to care. The new initiative aims to increase HIV testing, treatment initiation, adherence to therapy, and retention in HIV care.
Big Increase in Proportion of HIV+ People with Viral Suppression in US
- Details
- Category: Cascade of Care
- Published on Wednesday, 22 June 2016 00:00
- Written by Michael Carter
The proportion of people living with HIV receiving care in the U.S. who accessed antiretroviral therapy (ART) and achieved viral suppression increased substantially between 2009 and 2013, according to research published in the May 20 online edition of AIDS.
Less Frequent CD4 and Viral Load Monitoring Safe for People Doing Well on ART
- Details
- Category: HIV Treatment
- Published on Wednesday, 29 June 2016 00:00
- Written by Michael Carter
The frequency of routine monitoring for people treated with antiretrovirals who have viral suppression can be safely reduced from every 3 months to every 6 months, investigators from Europe and the U.S. reported in the June 1 edition of the Journal of Acquired Immune Deficiency Syndromes. However, people followed-up every 9 to 12 months were more likely to experience virological failure and also had lower CD4 cell increases compared to people monitored every 3 months.
Starting HIV Treatment at First Clinic Visit After Diagnosis Improves Outcomes
- Details
- Category: HIV Treatment
- Published on Wednesday, 15 June 2016 00:00
- Written by Liz Highleyman
A South African program aimed at shortening the usual process of HIV diagnosis, counseling, and preparation for antiretroviral therapy (ART) led to more people initiating treatment and achieving viral suppression, according to findings from the RapIT study published in the May 10 edition of PLoS Medicine.
ASM Microbe 2016: PRO 140 Antibody Injections Maintain Viral Suppression Off ART
- Details
- Category: Experimental HIV Drugs
- Published on Wednesday, 22 June 2016 00:00
- Written by Liz Highleyman
Subcutaneous injections of PRO 140, a monoclonal antibody that blocks HIV entry into cells, was well-tolerated and maintained undetectable viral load for more than a year after stopping antiretroviral therapy (ART) in patients with viral suppression, according to a study presented at the ASM Microbe 2016 meeting this week in Boston.
World Health Assembly Adopts Strategies for HIV, Viral Hepatitis, and STIs
- Details
- Category: HIV Treatment
- Published on Thursday, 09 June 2016 00:00
- Written by HIVandHepatitis.com
The 194 member states participating in the 69th World Health Assembly, which governs the World Health Organization (WHO) in late May unanimously approved the adoption of WHO's draft global health sector strategies for management of HIV, viral hepatitis, and sexually transmitted infections (STIs) through the year 2021.
More Articles...
- amfAR Announces New Round of HIV Cure Research Grants
- UNAIDS 90-90-90 Targets Could Prevent 2.5 Million HIV Deaths in South Africa
- June 5 Marks 35 Years Since First Report of AIDS
- Model Suggests There Are Fewer People with HIV in U.S. and More on Treatment
- Genvoya TAF Regimen Works Well with Improved Bone and Kidney Safety at 96 Weeks
Web Design and Development by